Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [815]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [815]

confidentiality , 566–67 , 569

in emergency rooms , 563–64

financing , 569

lack of, reasons for , 566–67

in primary care settings , 563 , 584

in schools , 51

system change considerations , 567–69

training programs , 568–69

international comparison , 346

locker searches , 565

multiple agents , 392

parental substance use and , 392

prevalence and trends , 343–46 , 343f–345 f, 345t–346 t

school professional findings , 601 , 602 t

subgroup differences , 345–46

versus substance use disorders , 563

zero-tolerance policies , 565

Substance use disorders , xxviii

animal models

biological research based on , 372–74 , 373 f, 374 f

of conditioned drug effects , 376–77

of drug reward , 374

genetic contributions , 384–85

of motivational effects of withdrawal , 375

anxiety disorders and , 170 , 228–29

brain executive inhibitory circuitry defects , 379–80

brain reward center dysregulation , 337 , 338

allostasis and , 378

animal models , 372–77 , 373 f, 374 f

imaging studies , 380–84

pharmacotherapy for , 402–3

clinical aspects , 347–72

alcohol , 356–63 , 357 t

club drugs , 372

cocaine/stimulants , 349–53 , 352 t

“ecstasy” (MDMA), 367–68

GHB , 369–70

hallucinogens , 370–71

heroin/opioids , 347–49 , 347 t, 349 t

inhalants , 368–69

marijuana , 353–56

PCP , 371–72

rohypnol , 370

tobacco , 363–67

comorbidity

anxiety disorders , 409–10

attention-deficit/hyperactivity disorder , 408

bipolar disorder , 23 , 408–9

data sources , 342–43

depression , 9 , 37 , 409

eating disorders , 272 , 273

treatment , 392 , 399–400 , 407–10

definitions , 336 , 568–69

detoxification , 403–4

developmental theories , 413–16

drug-related cues , 382–84

epidemiology , 339–47

genetics , xxviii, 384–89 , 415–16

identification , 563 , 568–69 . See also Substance use, identification

mediating factors , 417 , 417 t

molecular aspects , 377–78

neuroadaptations , 378

neurobiology , 372–84

overview , 336–39

pharmacotherapy , 401–10

abstinence and relapse prevention , 404–7

comorbidity and , 407–10

detoxification , 403–4

to reduce drug reward and craving , 402–3

prevention programs , 417–26

future directions and challenges , 422 , 426

indicated , 421

model, summaries and reviews , 422 , 423t–425 t

multilevel , 421–22

selective , 421

theoretical and conceptual models , 412

universal , 417–21

psychosocial therapy , 393–401

assessment issues , 399

comorbidity and , 399–400

disease model approaches , 398

evaluation studies , 393–94

inpatient approaches , 393–94

motivational approaches , 397–98

multisite studies , 399

multisystem approaches , 395–96

outpatient approaches , 394

process research and mechanisms of action , 399

randomized clinical trials , 394–99

research agenda , 428–29

risk factors and protective factors , 412–13

schizophrenia and , 79

suicide and , 434 , 437

treatment , 392–410 , 618–19

access to

barriers , 569–71

for step-down services , 575

system change considerations , 571–72

credentialing process , 570–71

financing mechanisms , 571 , 572

gaps , 562

gender differences , 562

matched to clinical prototypes , 573

obstacles , 392–93

recommended expansion of capacity , 571–72

service delivery systems , 572–76

emerging trends , 576–77

limited assessment practices , 572–74

end p.815